in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/fine chemicals roundup—5 August 2014
4:08 AM MDT | August 5, 2014 | Deepti Ramesh
FDA issues warning letter to API producer in China The US FDA issued a warning letter on 9 July to the active pharmaceutical ingredient (API) manufacturing facility of Zhejiang Jiuzhou Pharmaceutical and its export subsidiary, Zhejiang Zonebanner Jiuzhou Imp. & Exp. Co., which are both located at Taizhou, China, for violations of cGMP and misbranding. An FDA inspection from 21–24 October 2013 at the Taizhou facility identified deviations from cGMP for the manufacture of APIs, FDA says. The warning letter was published in the FDA web site on 29 July. In...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee